| __timestamp | MorphoSys AG | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 9689000 | 2652041 |
| Thursday, January 1, 2015 | 10431000 | 2361587 |
| Friday, January 1, 2016 | 9618000 | 4472869 |
| Sunday, January 1, 2017 | 12348000 | 5030957 |
| Monday, January 1, 2018 | 28310241 | 4988941 |
| Tuesday, January 1, 2019 | 59336147 | 5196412 |
| Wednesday, January 1, 2020 | 159145941 | 6652774 |
| Friday, January 1, 2021 | 199800000 | 18418247 |
| Saturday, January 1, 2022 | 90225000 | 24827066 |
| Sunday, January 1, 2023 | 92538000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Data in motion
In the ever-evolving biotech industry, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Opthea Limited and MorphoSys AG from 2014 to 2023. Over this period, MorphoSys AG's SG&A expenses surged by over 850%, peaking in 2021. In contrast, Opthea Limited's expenses grew by approximately 1,480%, with a notable spike in 2023.
These trends highlight the dynamic nature of financial management in biotech, where strategic spending can drive innovation and market positioning.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MorphoSys AG
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Opthea Limited
Regeneron Pharmaceuticals, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
BeiGene, Ltd. or Opthea Limited: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Insmed Incorporated and MorphoSys AG
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and MorphoSys AG
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs MorphoSys AG Trends and Insights
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and MorphoSys AG
Alkermes plc and MorphoSys AG: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.